Welcome to our dedicated page for ETRACS Whitney US Critical Techs ETN SEC filings (Ticker: WUCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for WUCT aggregates regulatory documents tied to ETRACS Whitney US Critical Technologies ETNs issued by UBS AG, a foreign private issuer. The core filings here are Forms 6-K, which provide interim financial and legal updates that are incorporated by reference into UBS AG’s Form F-3 registration statement for securities offerings.
In these Form 6-K reports, UBS AG discloses consolidated capitalization in US dollars under IFRS Accounting Standards, detailing short-term and long-term debt issued by UBS AG and its subsidiaries, funding from UBS Group AG, equity attributable to shareholders and non-controlling interests, and total capitalization. Such information helps investors understand the broader balance sheet context of the issuer behind the WUCT-linked ETNs.
The filings also explain how specific 6-K reports are incorporated into UBS AG’s Form F-3 registration statement and any outstanding prospectuses or offering circulars that reference those 6-Ks. This structure means that updates filed on Form 6-K become part of the official documentation for securities, including the ETRACS Whitney US Critical Technologies ETNs associated with WUCT.
Another Form 6-K on this page consists of the opinion of Homburger AG, acting as special Swiss counsel to UBS AG, which is filed as an exhibit to the Form F-3 registration statement and replaces a prior opinion. This highlights the role of legal opinions in UBS AG’s securities registration process.
On Stock Titan, users can access these filings in one place, with AI-powered tools available to summarize key sections, highlight important capitalization and legal disclosures, and help interpret how each new Form 6-K or related document fits into UBS AG’s overall reporting framework for the WUCT-linked ETNs.
UBS AG (NASDAQ:WUCT) has filed a Rule 424(b)(2) prospectus supplement for the launch of Capped Leveraged Buffered S&P 500 Index-Linked Medium-Term Notes maturing in roughly 13-15 months. The notes provide 250 % upside participation on positive S&P 500 performance, but gains are capped by a maximum settlement of $1,100.50–$1,118.00 per $1,000 face amount (equivalent to a cap level of about 104.02 %–104.72 % of the initial index level).
Downside risk is partially mitigated: investors are repaid principal if the index falls ≤10 %, yet losses accelerate to ≈1.1111 % per 1 % decline beyond that buffer, resulting in potential loss of the entire investment. The notes pay no interest or dividends and expose holders to UBS credit risk.
The preliminary estimated initial value is $957.50–$987.50 (95.75–98.75 % of face), versus a 100 % issue price. Gross proceeds will be reduced by a 1.08 % underwriting discount, leaving net proceeds at 98.92 % of face. Secondary-market trading is expected to be limited and may occur at prices below intrinsic value. The filing highlights extensive risk factors, including market volatility, liquidity constraints and conflicts of interest stemming from UBS Securities LLC’s dual role as underwriter and market maker.
UBS AG has filed a 424B2 prospectus supplement for the ETRACS Whitney US Critical Technologies ETN (NYSE:WUCT). The issue is a series of Trigger Callable Contingent Yield Notes maturing 12 Jul 2028 and linked to the worst performer of the Nasdaq-100, Russell 2000 and S&P 500 indices. Investors may receive a 10.15% per-annum contingent coupon on any monthly observation date when all three indices close at or above 70 % of their respective initial levels. UBS can redeem the notes in whole on any observation date after three months, paying par plus the applicable coupon.
If the notes are not called and any index finishes below the 70 % downside threshold at final valuation, repayment is reduced one-for-one with the weakest index’s decline, potentially to zero. The preliminary estimated initial value is $935.20-$965.20 per $1,000 face, reflecting the $2.50 underwriting discount and UBS funding costs. The notes are unsecured obligations of UBS, will not be listed on any exchange, and are subject to both market and issuer credit risk.
- Trade date: 7 Jul 2025 Settlement: 10 Jul 2025 (T+3)
- Maturity: 12 Jul 2028
- Coupon barrier & downside threshold: 70 % of initial level
- Issuer call feature: Monthly, beginning after 3 months
- Estimated initial value: 93.5-96.5 % of par CUSIP: 90308V6K2
Key risks disclosed include full principal loss if thresholds are breached, no guarantee of any coupon, early call risk that caps income, liquidity constraints and UBS’s creditworthiness.